PALO ALTO, May 27, 2015 — King & Spalding advised SciClone Pharmaceuticals (Nasdaq: SCLN) a U.S.-based, China-focused specialty pharmaceutical company, in a transaction with Theravance Biopharma, Inc. (Nasdaq: TBPH) granting SciClone exclusive development and commercial rights for the antibiotic VIBATIV® (telavancin) in China and certain adjacent territories. VIBATIV is an anti-infective therapy for difficult-to-treat infections.
The King & Spalding team included Silicon Valley-based partner Tom Duley and associates Stephen Abreu and Longbo Wang, all of whom are corporate lawyers focused on the life sciences industry.
Additional information on the agreement between SciClone and Theravance can be found here.
About King & Spalding
Celebrating more than 125 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 800 lawyers in 17 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.